Provided by Tiger Fintech (Singapore) Pte. Ltd.

IN8bio, Inc.

2.21
-0.0499-2.21%
Volume:21.60K
Turnover:48.07K
Market Cap:10.03M
PE:-0.17
High:2.29
Open:2.29
Low:2.19
Close:2.26
52wk High:17.64
52wk Low:1.98
Shares:4.54M
Float Shares:4.03M
Volume Ratio:0.43
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0307
EPS(LYR):-17.0525
ROE:-165.56%
ROA:-69.05%
PB:0.66
PE(LYR):-0.13

Loading ...

In8bio, Inc. Reports Improved Financial Performance

TIPRANKS
·
Aug 08

IN8bio Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

IN8bio Q2 EPS $(1.24) Beats $(1.70) Estimate

Benzinga
·
Aug 08

IN8BIO Inc. Announces Promising New Data from INB-200 Clinical Trial, Demonstrating Extended Progression-Free Survival in Glioblastoma Patients

Reuters
·
Aug 08

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire
·
Aug 08

IN8bio Regains Nasdaq Compliance with Bid Price Rule

TIPRANKS
·
Jul 01

Top Premarket Decliners

MT Newswires Live
·
Jun 09

IN8bio Inc trading halted, news pending

TIPRANKS
·
Jun 06

IN8BIO Inc. Announces 1-for-30 Reverse Stock Split Effective June 5, 2025

Reuters
·
Jun 04

IN8BIO Inc. Publishes Presentation on Harnessing Gamma-Delta T Cell Therapies for Oncology and Autoimmune Diseases

Reuters
·
Jun 04

IN8bio’s Promising Clinical Trial Results and Strategic Developments Justify Buy Rating

TIPRANKS
·
Jun 02

IN8BIO Inc. Unveils Presentation on Harnessing the Power of Gamma-Delta T Cells for Cancer Treatment

Reuters
·
Jun 02

BRIEF-In8bio Presents Positive Phase 1 Data Of Inb-200 In Newly Diagnosed Gbm Demonstrating Prolonged Progression-Free Survival

Reuters
·
Jun 02

IN8bio presents Phase 1 data on INB-200 in newly diagnosed GBM

TIPRANKS
·
Jun 02

Mizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)

TIPRANKS
·
May 09

IN8bio’s Strategic Growth and Development: Buy Rating Affirmed by Soumit Roy

TIPRANKS
·
May 09

Promising Developments and Financial Stability Support Buy Rating for IN8bio

TIPRANKS
·
May 08

IN8bio Q1 EPS $(0.07), Inline

Benzinga
·
May 08

IN8BIO Reports Q1 2025 Net Loss of $5.6M, EPS Improves to $0.07 Loss from $0.20, Cash Position at $11.9M

Reuters
·
May 08

Press Release: IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Dow Jones
·
May 08